ADVFN Logo
Registration Strip Icon for alerts Register for real-time alerts, custom portfolio, and market movers

ABBV AbbVie Inc

166.02
1.36 (0.83%)
Last Updated: 13:03:23
Delayed by 15 minutes

Period:

Draw Mode:

Volume 2,253,636
Bid Price
Ask Price
News -
Day High 166.60

Low
130.9601

52 Week Range

High
182.89

Day Low 163.25
Company Name Stock Ticker Symbol Market Type
AbbVie Inc ABBV NYSE Common Stock
  Price Change Change Percent Stock Price Last Traded
1.36 0.83% 166.02 13:03:23
Open Price Low Price High Price Close Price Prev Close
164.92 163.25 166.60 164.66
Trades Volume VWAP Dollar Volume Avg Volume 52 Week Range
33,469 2,253,636 $ 164.92 $ 371,669,897 - 130.9601 - 182.89
Last Trade Time Type Quantity Stock Price Currency
13:03:23 100 $ 166.02 USD

AbbVie (ABBV) Options Flow Summary

Overall Flow

Bearish

Net Premium

-1M

Calls / Puts

166.67%

Buys / Sells

70.59%

OTM / ITM

33.33%

Sweeps Ratio

0.00%

AbbVie Inc Financials

Market Cap Shares in Issue Float Revenue Profit/Loss EPS PE Ratio
292.69B 1.77B - 54.5B 4.86B 2.75 60.19
Short Interest Dividends Per Share Dividend Yield Ex-Div Date Insider B/S Insider % Owned
- - - -

more financials information »

AbbVie News

Loading Messages....

{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}}

Loading Messages....


No posts yet, be the first! No ABBV Message Board. Create One! See More Posts on ABBV Message Board See More Message Board Posts

Historical ABBV Price Data

Period Open High Low VWAP Avg. Daily Vol Change %
1 Week164.22167.44160.00162.975,374,0501.801.10%
1 Month177.20182.30160.00171.385,204,692-11.18-6.31%
3 Months165.34182.89160.00174.465,676,0230.680.41%
6 Months148.92182.89135.85161.235,624,70317.1011.48%
1 Year158.49182.89130.9601153.295,400,1587.534.75%
3 Years108.26182.89105.56141.836,090,94357.7653.35%
5 Years77.60182.8962.55114.657,157,02788.42113.94%

AbbVie Description

AbbVie is a pharmaceutical company with a strong exposure to immunology and oncology. The firm's top drug, Humira, represents close to half of the company's current profits. The company was spun off from Abbott in early 2013. The recent acquisition of Allergan adds several new drugs in aesthetics and women's health.

Your Recent History

Delayed Upgrade Clock